All Stories

  1. Multiparametric MRI and imaging transcriptomics reveal molecular and cellular correlates of neurodegeneration in experimental multiple system atrophy
  2. Pharmacologic NLRP3 Inhibition Modulates Parkinson’s Disease-Associated Microglial Transcriptomic Signatures and Mitigates α-Synuclein–Triggered Neurodegeneration
  3. Transcriptional dysregulation in the cerebellum triggered by oligodendroglial α-synucleinopathy: insights from a transgenic mouse into the early disease mechanisms of MSA
  4. Nigral Neuroinflammation and Dopaminergic Neurons in Parkinson's Disease and Atypical Parkinsonisms
  5. Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions
  6. Transcriptomic insights into multiple system atrophy from a PLP-α-synuclein transgenic mouse model
  7. Genome sequence analyses identify novel risk loci for multiple system atrophy
  8. Gregor K. Wenning: a brilliant mind
  9. Epsin2, a novel target for multiple system atrophy therapy via α-synuclein/FABP7 propagation
  10. Multiple system atrophy: at the crossroads of cellular, molecular and genetic mechanisms
  11. A Mouse Model of Multiple System Atrophy: Bench to Bedside
  12. Microglia in Parkinson’s Disease
  13. Host oligodendrogliopathy and ɑ-synuclein strains dictate disease severity in multiple system atrophy
  14. The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy
  15. Spreading of Aggregated α-Synuclein in Sagittal Organotypic Mouse Brain Slices
  16. Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy
  17. The Concept of α-Synuclein Strains and How Different Conformations May Explain Distinct Neurodegenerative Disorders
  18. Toll-like receptor 4 deficiency facilitates α-synuclein propagation and neurodegeneration in a mouse model of prodromal Parkinson's disease
  19. Is Multiple System Atrophy a Prion-like Disorder?
  20. Current experimental disease-modifying therapeutics for multiple system atrophy
  21. Neuropathology of multiple system atrophy: Kurt Jellinger`s legacy
  22. ATH434 Reduces α‐Synuclein‐Related Neurodegeneration in a Murine Model of Multiple System Atrophy
  23. Phenotypic Characterization and Brain Structure Analysis of Calcium Channel Subunit α2δ-2 Mutant (Ducky) and α2δ Double Knockout Mice
  24. Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease
  25. Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance
  26. From Synaptic Protein to Prion: The Long and Controversial Journey of α-Synuclein
  27. Signs of early cellular dysfunction in multiple system atrophy
  28. Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies
  29. Signs of Chronic Hypoxia Suggest a Novel Pathophysiological Event in α‐Synucleinopathies
  30. Shock waves promote spinal cord repair via TLR3
  31. Assessment of the Retina of Plp-α-Syn Mice as a Model for Studying Synuclein-Dependent Diseases
  32. Transcriptional profiling of multiple system atrophy cerebellar tissue highlights differences between the parkinsonian and cerebellar sub-types of the disease
  33. MSA: From basic mechanisms to experimental therapeutics
  34. Genes to treat excitotoxicity ameliorate the symptoms of the disease in mice models of multiple system atrophy
  35. High-salt diet does not boost neuroinflammation and neurodegeneration in a model of α-synucleinopathy
  36. The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy
  37. Neuroinflammation and Glial Phenotypic Changes in Alpha-Synucleinopathies
  38. Induced pluripotent stem cells in multiple system atrophy: recent developments and scientific challenges
  39. L-dopa response pattern in a rat model of mild striatonigral degeneration
  40. Increased anxiety-like behavior following circuit-specific catecholamine denervation in mice
  41. Anle138b modulates α‐synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy
  42. Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy
  43. Limited effects of dysfunctional macroautophagy on the accumulation of extracellularly derived α-synuclein in oligodendroglia: implications for MSA pathogenesis
  44. Translational therapies for multiple system atrophy: Bottlenecks and future directions
  45. The Relevance of Iron in the Pathogenesis of Multiple System Atrophy: A Viewpoint
  46. Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies
  47. Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting
  48. Multiple system atrophy: experimental models and reality
  49. Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathy
  50. Lower Affinity of Isradipine for L-Type Ca2+ Channels during Substantia Nigra Dopamine Neuron-Like Activity: Implications for Neuroprotection in Parkinson's Disease
  51. Very late-onset pure autonomic failure
  52. Distinct Parameters in the EEG of the PLP α-SYN Mouse Model for Multiple System Atrophy Reinforce Face Validity
  53. Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy
  54. Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy
  55. Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications
  56. Microglia activation as a therapeutic target in multiple system atrophy: the timing, the good and the bad
  57. Preface
  58. Review: Multiple system atrophy: emerging targets for interventional therapies
  59. Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies
  60. Glia and alpha-synuclein in neurodegeneration: A complex interaction
  61. Overexpression of α-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity
  62. Shock Wave Treatment Protects From Neuronal Degeneration via a Toll‐Like Receptor 3 Dependent Mechanism: Implications of a First‐Ever Causal Treatment for Ischemic Spinal Cord Injury
  63. Involvement of Peripheral Nerves in the Transgenic PLP-α-Syn Model of Multiple System Atrophy: Extending the Phenotype
  64. Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder
  65. Alpha-synuclein immunoreactivity patterns in the enteric nervous system
  66. Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications
  67. Animal models of multiple system atrophy
  68. Multiple System Atrophy: Genetic or Epigenetic?
  69. Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies
  70. Towards translational therapies for multiple system atrophy
  71. CaV1.2 Calcium Channel Expression in Reactive Astrocytes is associated with the Formation of Amyloid-β Plaques in an Alzheimer's Disease Mouse Model
  72. Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: Experimental evidence
  73. Intact Olfaction in a Mouse Model of Multiple System Atrophy
  74. Bladder dysfunction in a transgenic mouse model of multiple system atrophy
  75. Models of Multiple System Atrophy
  76. Cell Fate Analysis of Embryonic Ventral Mesencephalic Grafts in the 6-OHDA Model of Parkinson's Disease
  77. Toll‐like receptor 4 is required for α‐synuclein dependent activation of microglia and astroglia
  78. The Role of Glia in Alpha-Synucleinopathies
  79. Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy
  80. Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-Like Degeneration in a Transgenic Mouse Model
  81. Toll-Like Receptor 4 Promotes α-Synuclein Clearance and Survival of Nigral Dopaminergic Neurons
  82. Mesenchymal Stem Cells in a Transgenic Mouse Model of Multiple System Atrophy: Immunomodulation and Neuroprotection
  83. Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts
  84. Nogo-B is associated with cytoskeletal structures in human monocyte-derived macrophages
  85. Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy
  86. Targeted overexpression of human α-synuclein in oligodendroglia induces lesions linked to MSA -like progressive autonomic failure
  87. Kappa opioid receptor activation blocks progressive neurodegeneration after kainic acid injection
  88. Multiple system atrophy: an update
  89. Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy
  90. Striatal transplantation for multiple system atrophy — Are grafts affected by α-synucleinopathy?
  91. Recent developments in multiple system atrophy
  92. Striatal transplantation in a rodent model of multiple system atrophy: Effects on L-Dopa response
  93. Multiple system atrophy: A primary oligodendrogliopathy
  94. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy
  95. Axl and Growth Arrest–Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme
  96. Microglial activation mediates neurodegeneration related to oligodendroglial α-synucleinopathy: Implications for multiple system atrophy
  97. High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence
  98. Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy
  99. Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy
  100. Animal models of multiple system atrophy
  101. Oxidative Stress in Transgenic Mice with Oligodendroglial α-Synuclein Overexpression Replicates the Characteristic Neuropathology of Multiple System Atrophy
  102. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats
  103. In vitro models of multiple system atrophy
  104. Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy)
  105. Failure of caspase inhibition in the double-lesion rat model of striatonigral degeneration (multiple system atrophy)
  106. Effects of pulsatile l-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy)
  107. Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment
  108. Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration
  109. Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy)
  110. Tumor necrosis factor-?-induced cell death in U373 cells overexpressing ?-synuclein
  111. Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys
  112. Freezing of gait in postmortem‐confirmed atypical parkinsonism
  113. Ultrastructure of α-synuclein-positive aggregations in U373 astrocytoma and rat primary glial cells
  114. Overstimulation of the α1B-adrenergic receptor causes a “seizure plus” syndrome
  115. Glial cell death induced by overexpression of ?-synuclein
  116. Multiple System Atrophy
  117. Failure of Neuroprotection by Embryonic Striatal Grafts in a Double Lesion Rat Model of Striatonigral Degeneration (Multiple System Atrophy)
  118. γ-Aminobutyric acid-immunoreactive neurons in the amygdala of the rat – sex differences and effect of early postnatal castration
  119. Sex and age differences of neurons expressing gaba‐immunoreactivity in the rat bed nucleus of the stria terminalis